Valdés I, Gil L, Lazo L, Hermida L, Guillén G, Izquierdo A, Suzarte E, Cobas K, Guzmán MG Thao P, Anh DH, Yen P, Duc LH, Trung DL, Pérez, Y, Ramírez R, Álvarez M, Romero Y, Yaugel M, Marcos E, Tuan DD, Dan HN, Silva JÁ, González S, Vázquez M, Méndez A, Martín A

Language: English
References: 15
Page: 1501-1504
PDF size: 266.52 Kb.

ABSTRACT

Dengue, is one of the most important emerging disease around the world. Currently, only one vaccine has been approved and licensed against DENV, Dengvaxia®; however, its use is limited due to evidences of the risk of cause severe dengue under particular circumstances. For that, the development of new vaccine and/or immunization strategies continue be a priority to the scientific community. Vaccine candidates based on recombinant proteins are considered alternative approaches to solve the main disadvantages of attenuated vaccines, but these usually requiring adjuvants by their lower immunogenicity. This work describes the results in prime-boost schedules combining two different vaccine candidates: recombinant proteins and live attenuated virus. Firstly, we evaluated the capacity of Tetra DIIIC vaccine candidate to boost the memory immune response previously generated in DENV-immune monkeys. As results, the administration of Tetra DIIIC eight months later of the infection recalls the DENV specific memory B- and T-cell response. A second study, we tested in monkeys the combination of Tetra DIIIC with the LATV (TV005). This study demonstrates that animals Tetra DIIIC primed and later boosted with TV005 develop neutralizing antibodies against the four DENV serotypes, and the immune response induced reduces significantly LATV viremia. All these results highlight the possibility to combine the Tetra DIIIC vaccine candidate with LATV in a prime-boost strategy, and support these strategies as alternative approaches solving the troubles associated with each individual antigen. This work received the Annual Award of the Cuban Academy of Sciences for the year 2019.

REFERENCES

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496:504-7.

2. Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol. 2002;10:100-3.

3. Halstead SB. Dengue. London: Imperial College Press; 2008.

4. Russell PK, Halstead SB. Challenges to the design of clinical trials for liveattenuated tetravalent dengue vaccines. PLoS Negl Trop Dis. 2016;10:e0004854.

5. Feinberg MB, Ahmed R. Advancing dengue vaccine development. Science. 2017;358:865-6.

6. Guy B. Immunogenicity of sanofi pasteur tetravalent dengue vaccine. J Clin Virol. 2009;46(Suppl 2):S16-9.

7. Weiskopf D, Angelo MA, de Azeredo EL, Sidney J, Greenbaum JA, Fernando AN, et al. Comprehensive analysis of dengue virus-specific responses supports an HLAlinked protective role for CD8+ T cells. Proc Natl Acad Sci USA. 2013;110:E2046-53.

8. Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M, Machabert T, et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018;379:327-40.

9. Wilder-Smith A. Serostatus-dependent performance of the first licensed dengue vaccine: implications for travellers. J Travel Med. 2018;25:tay057.

10. Whitehead SS. Development of TV003/ TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine ifferent from the Sanofi-Pasteur CYD vaccine? Exp Rev Vaccin. 2016;15:509-17.

11. Osorio JE, Wallace D, Stinchcomb DT. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. Exp Rev Vaccin. 2016;15:497-508.

12. Gil L, Lazo L, Valdés I, Suzarte E, Yen P, Ramirez R, et al. The tetravalent formulation of domain III-capsid proteins recalls memory B- and T-cell responses induced in monkeys by an experimental dengue virus infection. Clin Transl Immunol. 2017;6:e148.

13. Valdés I, Izquierdo A, Cobas K, Thao P, Anh DH, Duc LH, et al. A heterologous prime-boost strategy for immunization against Dengue virus combining the Tetra DIIIC subunit vaccine candidate with the TV005 live-attenuated tetravalent vaccine. J Gen Virol. 2019;100:975-84.

14. Suzarte E, Marcos E, Gil L, Valdés I, Lazo L, Ramos Y, et al. Generation and characterization of potential dengue vaccine candidates based on domain III of the envelope protein and the capsid protein of the four serotypes of dengue virus. Arch Virol. 2014;159:1629-40.

15. Durbin AP, Kirkpatrick BD, Pierce KK, Carmolli MP, Tibery CM, Grier PL, et al. A 12-month-interval dosing study in adults indicates that a single dose of the national institute of allergy and infectious diseases tetravalent dengue vaccine induces a robust neutralizing antibody response. J Infect Dis. 2016;214:832-5.